The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Abstract
Objective. —To examine more closely the association between apolipoprotein E (APOE) genotype and Alzheimer disease (AD) by age and sex in populations of various ethnic and racial denominations. Data Sources. —Forty research teams contributed data onAPOEgenotype, sex, age at disease onset, and ethnic background for 5930 patients who met criteria for probable or definite AD and 8607 controls without dementia who were recruited from clinical, community, and brain bank sources. Main Outcome Measures. —Odds ratios (ORs) and 95% confidence intervals (Cls) for AD, adjusted for age and study and stratified by major ethnic group (Caucasian, African American, Hispanic, and Japanese) and source, were computed forAPOEgenotypes ∈2/∈2,∈2/∈3,∈2/∈4,∈3/∈4 and ∈4/∈4 relative to the ∈3/∈3 group. The influence of age and sex on the OR for each genotype was assessed using logistic regression procedures. Results. —Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes ∈2/∈4 (OR=2.6, 95% Cl=1.6-4.0), ∈3/∈4 (OR=3.2, 95% Cl=2.8-3.8), and ∈4/∈4 (OR=14.9, 95% CI=10.8-20.6); whereas, the ORs were decreased for people with genotypes ∈2/∈2 (OR=0.6, 95% Cl=0.2-2.0) and ∈2/∈3 (OR=0.6, 95% Cl=0.5-0.8). TheAPOE∈4-AD association was weaker among African Americans and Hispanics, but there was significant heterogeneity in ORs among studies of African Americans (P<.03). TheAPOE∈4—AD association in Japanese subjects was stronger than in Caucasian subjects (∈3/∈4: OR=5.6, 95% Cl=3.9-8.0; ∈4/∈4: OR=33.1, 95% Cl=13.6-80.5). The ∈2/∈3 genotype appears equally protective across ethnic groups. We also found that among Caucasians,APOEgenotype distributions are similar in groups of patients with AD whose diagnoses were determined clinically or by autopsy. In addition, we found that theAPOE∈4 effect is evident at all ages between 40 and 90 years but diminishes after age 70 years and that the risk of AD associated with a given genotype varies with sex. Conclusions. —TheAPOE∈4 allele represents a major risk factor for AD in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women. The association betweenAPOE∈4 and AD in African Americans requires clarification, and the attenuated effect ofAPOE∈4 in Hispanics should be investigated further.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The greatest risk factors for late-onset Alzheimer's are older age, 62,63 genetics 64,65 -especially the e4 form of the apolipoprotein E (APOE) gene -and having a family history of Alzheimer's.[66][67][68][69]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [65]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Also, previous studies of clinically and neuropathologically characterized cases and controls may have been too small to demonstrate that APOE2 homozygotes have an even lower OR than the relatively low-risk APOE2/3 group due to the paucity of APOE2 homozygotes, who comprise <1% of the general population1,4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Fourth, findings from our non-Hispanic White groups cannot yet be extended to other ethnic and racial groups4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“APOE is genetically linked to late-onset sporadic Alzheimer’s disease (LOAD), with APOE4 being a significant risk factor, APOE3 considered the “neutral” allele, and APOE2 exerting a protective role against LOAD [6, 7].”
In the citing paper
“In addition, APOE4 is linked to hypercholesterolemia and increased risk of cardiovascular disorders (CVD) [7, 41]”
In the citing paper
“Compared to ε3 homozygotes, individuals with one or two ε4 alleles harbor approximately 3 and 15 times increased risk, respectively”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“whereas carriers of the protective ε2 allele have an estimated 1.7 times decreased risk [1]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“Between 45% and 50% of AD patients carry at least one APOE4 allele compared to only 15% of age-matched healthy controls.5,11”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [11]
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“In humans, the APOE2/4 genotype confers an intermediate risk, higher than that of APOE3/3 but lower than APOE3/4 and APOE4/4 5,6 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“Population studies have demonstrated that the ε4 allele increases the risk of developing AD by either 3-fold (1 allele) or 12-fold (2 alleles) [6]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [6]
In the citing paper
“ApoE4, found in 65–80% of cases of sporadic and familial Alzheimer's disease, increases the occurrence of AD by ∼12 fold in two ɛ4 allele carriers, compared with those with no ɛ4 allele (Farrer et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Farrer et al., 1997
In the citing paper
“The APOE4 allele is a major genetic risk factor for late-onset AD and was previously shown to accelerate AD progression in humans and in mouse models 6-11 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [43]
In the citing paper
“Separately, clinical studies have reported that women APOE ε4 carriers had a higher risk of Alzheimer’s dementia than men carriers [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“Furthermore, a recent meta-analysis of 58000 participants showed that APOE ε3/ε4 women have the same increased odds of AD dementia as APOE ε3ε4 men have, in contrast to a previous meta-analysis which reported APOE ε4 women to carry a higher risk of Alzheimer’s dementia compared to APOE ε4 men [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“As APOE4 carriers make up 55–75% of AD cases17–20”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [18]
In the citing paper
“The initial intriguing observation that the APOEε4 allele increases AD risk differentially across races and ethnicities, with the greatest increase in risk seen in East Asian people, followed by white, then Black, then Hispanic people6, has now been confirmed by a larger meta-analysis using not only self-reported race and ethnicity but also global genetic ancestry to ascertain the biological basis”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“Rather, age and sex moderate the effects of the APOE genotype on AD risk so that the risk associated with the APOEε3/ε4 genotype is highest in women of ages 60–70 years (or 70–80 years according to ref. 6) but decreases in older women and equalizes to that of non-Hispanic White, Black and Hispanic men of the same age10.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“The APOE polymorphism is the most studied, successfully replicated, and well-established risk factor for AD where APOE*2 is the protective allele and APOE*4 is the risk allele as compared to APOE*3 [7–10].”
From Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk (2023) · cites this paper as [8]
In the citing paper
“The original association study implicating L28P with LOAD risk was carried out in a relatively small sample size.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“due to the complete linkage disequilibrium of L28P with APOE*4 (C112R)”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“it was associated with an elevated risk for AD [9]”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“In 1999, two groups independently identified a novel and rare missense mutation in the APOE gene [9, 10] in which the leucine residue is replaced by proline at codon 28 (L28P; rs769452).”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“with the East Asian population having a higher risk of AD associated with the APOE ε4 allele”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“while the effect of APOE ε4 is weaker in African American and Hispanic populations”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“The AD risk associated with common APOE alleles ε4 1 and ε2 2 is well established in European-ancestry individuals but varies considerably across other ancestries (Table 1). 3”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [3]
In the citing paper
“Among the AD susceptibility genes/loci identified to date, APOE remains the most significant genetic risk factor across populations.”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [8]
In the citing paper
“Although there is only about 20% of the population carrying the APOE ε4, this isoform is vastly enriched in AD patients with over 60% of symptomatic AD patients carrying at least one APOE ε4 allele”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Farrer et al 1997
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the dominant genetic risk factor for late-onset Alzheimer’s disease (AD).”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [5]
In the citing paper
“The genetic polymorphism of human apolipoprotein E (ApoE) has been shown to confer differential susceptibility to late-onset AD, which accounts for the majority of the AD cases (Farrer et al., 1997).”
From Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention (2018) · cites this paper as Farrer et al., 1997
In the citing paper
“occurs in approximately two-thirds of all cases [1–3]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer’s disease (AD)”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“In contrast, APOE3 is defined as risk-neutral while APOE2 represents the strongest genetic protective factor (Corder et al., 1994; Farrer et al., 1997; Reiman et al., 2020).”
From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Farrer et al., 1997
In the citing paper
“Since then, numerous studies have confirmed that possession of the ε4 allele is the strongest genetic risk factor for both AD and CAA, or a combination of both disorders (Bertram et al., 2007; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“However, in certain ethnic groups, the apoE ε4 allele seems to have either a weaker effect or no clear effect on AD (Farrer et al., 1997; Kalaria et al., 2008; Mayeux, 2003; Tang et al., 1998).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“Finally, it is important to note that the ε2 allele of apoE is associated with a lower risk for AD (Corder et al., 1994; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“APOE genotypes were in Hardy-Weinberg equilibrium in both cases and controls; their frequencies (Table 4) were similar to previous reports for the relevant age groups (44;47;48).”
From Association of ALS with head injury, cigarette smoking and APOE genotypes (2010) · cites this paper as [47]
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor for sporadic Alzheimer's Disease (AD).”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“An APOE ε4/ε4 individual of European ancestry has a sixteen-fold increase in AD risk and eighteen year earlier age at AD onset compared to a European ancestry individual carrying two copies of the more prevalent APOE ε3 allele 4 .”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“The global frequency of the human ε4 allele is 13.7%, and the frequency of ε4 carriers is increased to 40% in AD patients [452, 453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“Clinical incidence and average age of AD onset was found to be 91% at 68 years of age in ε4 homozygous carriers, 47% at 76 years of age in ε4 heterozygous carriers, and 20% at 84 years of age in non-ε4 individuals [453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“ApoE4 is present in roughly 20–25% of the human population, and apoE4 carriers account for 60–75% of AD cases in most clinical studies [11], highlighting the importance of apoE4 in AD pathogenesis.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“ApoE4 increases the risk and decreases the age of onset of AD in a gene dose dependent manner [4–11].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“the effect of APOEε4 has been reported to differ across ethnicities [58–61]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“the association between ε4 and disease is reported to be weaker among African-American and Hispanic individuals [58, 61, 62] and nonexistent among Nigerian individuals [63].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“APOEε2/APOEε4 individuals are still at increased risk for AD, suggesting the APOEε4 isoform exhibits some dominant effect over the APOEε2 isoform [58].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“Several studies have demonstrated APOE genotype has an exacerbated effect on disease risk in females [58]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Sorted by citations
Items 501–600 of 1,178
Non-familial Alzheimer's disease is mainly due to genetic factors
Ashford, J. W., & Mortimer, J. A. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4307 · Cited by 151
Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results
Baudron, C. R., Krolak‐Salmon, P., Quadrio, I., Mégraud, F., & Salles, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.021 · Cited by 152
“No curative treatment for dementia is available, and most of the currently identified risk factors such as age, sex, and genetic factors like apolipoprotein E allele 4 are not subject to intervention (Farrer et al., 1997).”
BackgroundHarris, F. M., Brecht, W. J., Xu, Q., Mahley, R. W., & Huang, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408127200 · Cited by 151
APOE genotype and cognitive functioning in a large age-stratified population sample.
Jorm, A. F., Mather, K. A., Butterworth, P., Anstey, K. J., Christensen, H. M., & Easteal, S. (2007) · Neuropsychology · doi:10.1037/0894-4105.21.1.1 · Cited by 158
Can Infections Cause Alzheimer's Disease?
Mawanda, F., & Wallace, R. B. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs007 · Cited by 151
Sex hormones, aging, and Alzheimer's disease.
Barron, A. M., & Pike, C. J. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/434 · Cited by 8
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy
Schmidt, S., Klaver, C. C. W., Saunders, A. M., Postel, E. A., De La Paz, M. A., Agarwal, A., Small, K. W., Udar, N., Ong, J. M., Chalukya, M. V., et al. (2002) · Ophthalmic Genetics · doi:10.1076/opge.23.4.209.13883 · Cited by 149
Moghadasian, M. H., McManus, B. M., Nguyen, L. B., Shefer, S., Nadji, M., Godin, D. V., Green, T. J., Hill, J. S., Yang, Y., Scudamore, C. H., et al. (2001) · The FASEB Journal · doi:10.1096/fj.01-0463com · Cited by 150
“Possible effects on human life span (25) and the onset of Alzheimer’s disease ( 40 ) have been also reported.”
BackgroundVardarajan, B. N., Ghani, M., Kahn, A., Sheikh, S., Sato, C., Barral, S., Lee, J. H., Cheng, R., Reitz, C., Lantigua, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24466 · Cited by 148
Caselli, R. J., Reiman, E. M., Locke, D. E. C., Hutton, M. L., Hentz, J. G., Hoffman‐Snyder, C., Woodruff, B. K., Alexander, G. E., & Osborne, D. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1306 · Cited by 153
Saleh, R. N. M., Hornberger, M., Ritchie, C. W., & Minihane, A. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01121-5 · Cited by 162
Reduced functional brain activity response in cognitively intact apolipoprotein E ε4 carriers
Lind, J., Persson, J., Ingvar, M., Larsson, A., Cruts, M., Broeckhoven, C. V., Adolfsson, R., Bäckman, L., Nilsson, L., Petersson, K. M., et al. (2006) · Brain · doi:10.1093/brain/awl054 · Cited by 149
“…contact journals.permissions@oxfordjournals.org Genetic studies have ameliorated these shortcomings by identifying the apolipoprotein E «4 allele (APOE «4) as a susceptibility gene for Alzheimer’s disease (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993; Farrer et al., 1997).”
BackgroundApolipoprotein E and Alzheimer Disease: An Update on Genetic and Functional Analyses
Saunders, A. M. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.9.751 · Cited by 147
Senile Dementia with Tangles (Tangle Predominant Form of Senile Dementia)
Jellinger, K. A., & Bancher, C. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00160.x · Cited by 148
Ferretti, M. T., Martínková, J., Biskup, E. M., Benke, T., Gialdini, G., Nedelská, Z., Rauen, K., Mantua, V., Religa, D., Hort, J., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14174 · Cited by 152
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 152
The Mitochondrial Spiral: An Adequate Cause of Dementia in the Alzheimer's Syndrome
Blass, J. P. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05576.x · Cited by 150
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 147
Roberts, J. S., Cupples, L. A., Relkin, N. R., Whitehouse, P. J., Green, R. C., & for the REVEAL (Risk Evaluation and Education for Alzheimer’s Disease) Study Group (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281883 · Cited by 146
Stein, J. L., Hua, X., Morra, J. H., Lee, S., Hibar, D. P., Ho, A. J., Leow, A. D., Toga, A. W., Sul, J. H., Kang, H. M., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.068 · Cited by 145
“Interactions with apolipoprotein E (APOE) ε4 allele The ε4 allele of the APOE gene is a well-validated genetic risk factor for AD (Farrer et al., 1997), and we and others have previously found that this allele is associated with temporal lobe atrophy (Hua et al., 2008) and with the rate of…”
Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142
Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis
Lambert, J.-C., Grenier-Boley, B., Chouraki, V., Heath, S., Zelenika, D., Fievet, N., Hannequin, D., Pasquier, F., Hanon, O., Brice, A., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100018 · Cited by 144
Tan, L., Yu, J., Zhang, W., Wu, Z., Zhang, Q., Liu, Q., Wang, W., Wang, H.-F., Ma, X., & Cui, W. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.08.007 · Cited by 146
Age dependency of risk factors for cognitive decline
Legdeur, N., Heymans, M. W., Comijs, H. C., Huisman, M. A., Maier, A. B., & Visser, P. J. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0876-2 · Cited by 155
APOE alleles and diet in brain aging and Alzheimer's disease
Yassine, H. N., & Finch, C. E. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00150 · Cited by 145
Stem cell therapy for Alzheimer's disease
Liu, X., Yang, L.-P., & Zhao, L. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.787 · Cited by 162
Apolipoprotein E controls the risk and age at onset of Parkinson disease
Li, Y. J., Hauser, M. A., Scott, W. K., Martin, E. R., Booze, M. W., Qin, X. J., Walter, J. W., Nance, M. A., Hubble, J. P., Koller, W. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000128089.53030.ac · Cited by 144
Human iPSC‐derived microglia: A growing toolset to study the brain's innate immune cells
Hasselmann, J., & Blurton‐Jones, M. (2020) · Glia · doi:10.1002/glia.23781 · Cited by 145
“In one elegant example, Lin et al., examined the effects of the APOE ε4 allele, the most significant AD risk gene (Farrer et al., 1997; Harold et al., 2009; Lambert et al., 2009), on the transcriptome and function of human microglia (Lin et al., 2018).”
BackgroundMandelblatt, J. S., Hurria, A., McDonald, B. C., Saykin, A. J., Stern, R. A., VanMeter, J. W., McGuckin, M., Traina, T., Denduluri, N., Turner, R. S., et al. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.09.006 · Cited by 155
Epidemiology of dementia in Asia: Insights on prevalence, trends and novel risk factors
Catindig, J.-A. S., Venketasubramanian, N., Ikram, M. K., & Chen, C. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.023 · Cited by 143
Analysis of the MIRIAD Data Shows Sex Differences in Hippocampal Atrophy Progression
Ardekani, B. A., Convit, A., & Bachman, A. H. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150780 · Cited by 141
Apostolova, L. G., & Thompson, P. M. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2007.10.026 · Cited by 149
“Computational anatomy techniques such as cortical pattern matching, automated ventricular segmentation, Freesurfer (Fischl & Dale, 2000; Fischl et al., 2004) and TBM, could likewise provide improved sensitivity and the much-needed evidence for therapeutic effects of anti-AD therapy on the living…”
MethodMaruyama, H., Toji, H., Harrington, C. R., Sasaki, K., Izumi, Y., Ohnuma, T., Arai, H., Yasuda, M., Tanaka, C., Emson, P. C., et al. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.236 · Cited by 144
Lipnicki, D. M., Makkar, S. R., Crawford, J. D., Thalamuthu, A., Kochan, N. A., Lima‐Costa, M. F., Costa, E., Ferri, C. P., Brayne, C., Stephan, B. C. M., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002853 · Cited by 142
Biological and environmental predictors of heterogeneity in neurocognitive ageing
Nyberg, L. H., Boraxbekk, C., Sörman, D. E., Hansson, P., Herlitz, A., Kauppi, K., Ljungberg, J. K., Lövheim, H., Lundquist, A., Adolfsson, A. N., et al. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101184 · Cited by 156
Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator.
Mutter, J., Naumann, J., Sadaghiani, C., Schneider, R., & Walach, H. (2004) · PubMed · Cited by 143
APOE genotype and cognitive decline in a middle-aged cohort
Blair, C. K., Folsom, A. R., Knopman, D. S., Bray, M. S., Mosley, T. H., & Boerwinkle, E. (2005) · Neurology · doi:10.1212/01.wnl.0000149643.91367.8a · Cited by 143
NDRG2: a novel Alzheimer's disease associated protein
Mitchelmore, C., Büchmann-Møller, S., Rask, L., West, M. J., Troncoso, J. C., & Jensen, N. A. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.003 · Cited by 143
“…genetic risk factors have been associated with the disorder, including the q4 allele of the apolipoprotein E (APOE) gene (Corder et al., 1993; Farrer et al., 1997; Saunders et al., 1993), mutations affecting the transcriptional activity of the APOE gene (Bullido et al., 1998; Lambert et al.,…”
BackgroundSchiele, F., Bacquer, D. D., Vincent‐Viry, M., Beisiegel†, U., Ehnholm, C., Evans, A., Kafatos, A., Martins, M. C., Sans, S., Sass, C., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00501-8 · Cited by 143
Welton, J. L., Loveless, S., Stone, T., von Ruhland, C., Robertson, N. P., & Clayton, A. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1369805 · Cited by 142
Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese
Takei, N., Miyashita, A., Tsukie, T., Arai, H., Asada, T., Imagawa, M., Shoji, M., Higuchi, S., Urakami, K., Kimura, H., et al. (2009) · Genomics · doi:10.1016/j.ygeno.2009.01.003 · Cited by 143
“Compared to the APOE-ɛ 3 allele, the APOE-ɛ 4 allele is a strong risk factor with an odds ratio (OR) of 2.0 – 4.0, the APOE-ɛ 2 allele being protective as to LOAD [7,8].”
InfluentialAGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE
Petersen, R. C. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70226-7 · Cited by 144
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Rocca, W. A., Shuster, L. T., Grossardt, B. R., Maraganore, D. M., Gostout, B. S., Geda, Y. E., & Melton, L. J. (2009) · Women s Health · doi:10.2217/17455057.5.1.39 · Cited by 144
Kim, J., Yoon, H., Basak, J., & Kim, J. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0248 · Cited by 141
“APOE IN ALZHEIMER’S DISEASE ApoE4, found in 65-80% of cases of sporadic and familial Alzheimer's disease, increases the occurrence of AD by ~12 fold in two 4 allele carriers, compared with those with no 4 allele (Farrer et al., 1997).”
BackgroundVemuri, P., Knopman, D. S., Lesnick, T. G., Przybelski, S. A., Mielke, M. M., Graff‐Radford, J., Murray, M. E., Roberts, R. O., Vassilaki, M. E., Lowe, V. J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0244 · Cited by 144
Culture, Ethnicity, and Level of Education in Alzheimer's Disease
Rosselli, M., Vélez-Uribe, I., Ahne, E., & Shihadeh, L. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01193-z · Cited by 154
Prevalence of Dementia in the United States
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Cited by 139
Cruchaga, C., Del‐Aguila, J. L., Saef, B., Black, K., Fernandez, M. V., Budde, J., Ibanez, L., Deming, Y., Kapoor, M., Tosto, G., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.013 · Cited by 138
The endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo
Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140
“Carriers of the ε4 allele of APOE are at a significantly increased risk of developing late-onset AD (Farrer et al., 1997).”
BackgroundPang, K., Jiang, R., Zhang, W., Yang, Z., Li, L., Shimozawa, M., Tambaro, S., Mayer, J., Zhang, B., Li, M., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00582-x · Cited by 147
Alzheimer’s disease: Insights from epidemiology
McDowell, I. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351474 · Cited by 140
APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction
Soto, I., Graham, L. C., Richter, H. J., Simeone, S. N., Radell, J. E., Grabowska, W., Funkhouser, W. K., Howell, M. C., & Howell, G. R. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002279 · Cited by 140
Beydoun, M. A., Boueiz, A., Abougergi, M. S., Kitner-Triolo, M. H., Beydoun, H. A., Resnick, S. M., O'Brien, R., & Zonderman, A. B. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.017 · Cited by 139
“…Lehmann et al., 2006; Martinez et al., 1998; Molero et al., 2001; Mortensen and Hogh, 2001; Payami et al., 1997; Swan et al., 2005) and an earlier meta-analysis indicated that sex was potentially an effect modifier in the ApoE genotype-Alzheimer's disease (AD) association (Farrer et al., 1997).”
BackgroundOn Jim Watson's APOE status: genetic information is hard to hide
Nyholt, D. R., Yu, C., & Visscher, P. M. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.198 · Cited by 137
Palmitoylation in Alzheimers disease and other neurodegenerative diseases
Cho, E., & Park, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.008 · Cited by 151
Effect of Apolipoprotein E on the Cerebral Load of Latent Herpes Simplex Virus Type 1 DNA
Burgos, J. S., Ramírez, C. D., Sastre, I., & Valdivieso, F. (2006) · Journal of Virology · doi:10.1128/jvi.00006-06 · Cited by 139
APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians
Gureje, O., Ogunniyi, A., Baiyewu, O., Price, B., Unverzagt, F. W., Evans, R. M., Smith‐Gamble, V., Lane, K. A., Gao, S., Hall, K. S., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20694 · Cited by 139
Glial cell dysregulation: a new perspective on Alzheimer disease
Rommy von Bernhardi, M. (2007) · Neurotoxicity Research · doi:10.1007/bf03033906 · Cited by 141
“The presence of the Apolipoprotein E4 (apoE4) allele, implicated in the clearance of A is an important risk factor in developing sporadic AD (Roses, 1996; Farrer et al., 1997).”
BackgroundCRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
Bhardwaj, S., Kesari, K. K., Rachamalla, M., Mani, S., Ashraf, G. M., Jha, S. K., Kumar, P., Ambasta, R. K., Dureja, H., Devkota, H. P., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.001 · Cited by 145
Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E ɛ4
Espeseth, T., Westlye, L. T., Fjell, A. M., Walhovd, K. B., Rootwelt, H., & Reinvang, I. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.030 · Cited by 135
“The APOE 4 associated risk for AD is also stronger for middle-aged ompared to older samples (Farrer et al., 1997).”
BackgroundAstroglial Regulation of Apolipoprotein E Expression in Neuronal Cells
Harris, F. M., Tesseur, I., Brecht, W. J., Xu, Q., Mullendorff, K., Chang, S., Wyss-Coray, T., Mahley, R. W., & Huang, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309475200 · Cited by 135
Cognitive Changes After Menopause: Influence of Estrogen
Henderson, V. W. (2008) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e318180ba10 · Cited by 138
Dietary Links to Alzheimer's Disease: 1999 Update
Grant, W. B. (1999) · Journal of Alzheimer s Disease · doi:10.3233/jad-1999-14-501 · Cited by 138
Current Alzheimer's disease clinical trials: Methods and placebo outcomes
Schneider, L. S. S., & Sano, M. C. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.038 · Cited by 137
Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review
Avgerinos, K. I., Kalaitzidis, G., Malli, A., Kalaitzoglou, D., Myserlis, E. P., & Lioutas, V. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8768-0 · Cited by 140
Apolipoprotein-E (Apoe) ε4 and cognitive decline over the adult life course
Rawle, M. J., Davis, D., Bendayan, R., Wong, A., Kuh, D., & Richards, M. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0064-8 · Cited by 137
Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene
Artiga, M. J., Bullido, M. J., Frank, A., Sastre, I., Recuero, M., Garcia, M. A., Lendon, C. L., Han, S. W., Morris, J. C., Vázquez, J., et al. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.12.1887 · Cited by 140
Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase
Atamna, H., & Kumar, R. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100414 · Cited by 142
Midlife Vascular Risk Factors and Alzheimer's Disease: Evidence from Epidemiological Studies
Tolppanen, A., Solomon, A., Soininen, H. S., & Kivipelto, M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120802 · Cited by 143
Association of APOE with tau-tangle pathology with and without β-amyloid
Farfel, J. M., Yu, L., Jager, P. L. D., Schneider, J. A., & Bennett, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.011 · Cited by 142
Periodontal disease, tooth loss and dementia: Is there a link? A systematic review
Tonsekar, P., Jiang, S. S., & Yue, G. (2017) · Gerodontology · doi:10.1111/ger.12261 · Cited by 148
Mosconi, L., Rinne, J. O., Tsui, W. H., Berti, V., Li, Y., Wang, H., Murray, J., Scheinin, N., Någren, K., Williams, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914141107 · Cited by 135
APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
Sampedro, F., Initiative, F. T. A. D. N., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5185 · Cited by 135
Genetic Aspects of Alzheimer Disease
Williamson, J., Goldman, J. S., & Marder, K. S. (2009) · The Neurologist · doi:10.1097/nrl.0b013e318187e76b · Cited by 142
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132
The genetic landscape of Alzheimer disease
Carmona, S., Hardy, J., & Guerreiro, R. J. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00026-0 · Cited by 140
Causes of Alzheimer's disease.
Muñoz, D. G., & Feldman, H. (2000) · PubMed Central · Cited by 136
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Genetics of Alzheimer's disease: new evidences for an old hypothesis?
Lambert, J., & Amouyel, P. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.02.002 · Cited by 141
Genes contributing to prion pathogenesis
Tamgüney, G., Giles, K., Glidden, D. V., Lessard, P., Wille, H., Tremblay, P., Groth, D., Yehiely, F., Korth, C., Moore, R. C., et al. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/001255-0 · Cited by 131
“…Reference Results Amyloid beta (A4) precursor protein (App) Mouse orthologues colocalize with PrPC; human orthologues are associated with AD Farrer et al. (1997); Schmitt-Ulms et al. (2004) Table 2 Human APP695 Amyloid beta (A4) precursor-like protein (Aplp2) Human apolipoprotein E (APOE),…”
BackgroundTight junction modulation at the blood-brain barrier: Current and future perspectives
Hashimoto, Y., & Campbell, M. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183298 · Cited by 138
APOE Genotype, Family History of Dementia, and Alzheimer Disease Risk
Huang, W., Qiu, C., Strauss, E. I. V., Winblad, B. G., & Fratiglioni, L. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1930 · Cited by 134
Lambert, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.9.1511 · Cited by 132
“This risk factor accounts for ~45‐60% of cases ( 1 ).”
BackgroundZhao, L., Mao, Z., Woody, S. K., & Brinton, R. D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.011 · Cited by 132
“…the ε4 allele of the apolipoprotein E gene (APOE4), the strongest genetic risk factor for late-onset AD, has been associated with a far more pronounced risk for AD in women than in men (Altmann et al., 2014; Bretsky et al., 1999; Farrer et al., 1997; Mortensen and Hogh, 2001; Neurobiol Aging.”
BackgroundKöbe, T., Witte, A. V., Schnelle, A., Lesemann, A., Fabian, S., Tesky, V. A., Pantel, J., & Flöel, A. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.09.050 · Cited by 138
“…performance (Corder et al., 1993; Egan et al., 2003; Witte and Floel, 2012) andApoE4 allele carrier status is associatedwith higher risk of AD (Farrer et al., 1997), potential confounding factors if unevenly distributed between intervention groups in our small cohort of patients with MCI.”
Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden
Wirth, M., Villeneuve, S., Joie, R. L., Marks, S. M., & Jagust, W. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4612-13.2014 · Cited by 139
The influence of apoe status on episodic and semantic memory: Data from a population-based study.
Nilsson, L., Adolfsson, R., Bäckman, L., Cruts, M., Nyberg, L. H., Small, B. J., & Broeckhoven, C. V. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.645 · Cited by 132
Lind, J., Larsson, A., Persson, J., Ingvar, M., Nilsson, L., Bäckman, L., Adolfsson, R., Cruts, M., Sleegers, K., Broeckhoven, C. V., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.070 · Cited by 135
Microglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
The effects of APOE on the functional architecture of the resting brain
Trachtenberg, A. J., Filippini, N., Ebmeier, K. P., Smith, S. M., Karpe, F., & Mackay, C. E. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.059 · Cited by 133
Apolipoproteins and aging: emerging mechanisms
Smith, J. D. (2002) · Ageing Research Reviews · doi:10.1016/s1568-1637(02)00005-3 · Cited by 133
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
Bäcker‐Koduah, P., Paul, F., & Dörr, J.-M. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0120-8 · Cited by 134
THE PATTERNS OF NATURAL VARIATION IN HUMAN GENES
Crawford, D. C., Akey, D. T., & Nickerson, D. A. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162309 · Cited by 131
Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba
Hall, K., Murrell, J., Ogunniyi, A., Deeg, M., Baiyewu, O., Gao, S., Gureje, O., Dickens, J., Evans, R., Smith-Gamble, V., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194507.39504.17 · Cited by 128
Lahiri, D. K., Sambamurti, K., & Bennett, D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.024 · Cited by 131
Kim, S., Kim, M. J., Kim, S., Kang, H. S., Lim, S. W., Myung, W., Lee, Y., Hong, C. H., Choi, S. H., Na, D. L., et al. (2015) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2015.07.002 · Cited by 131
Exercise, APOE genotype, and the evolution of the human lifespan
Raichlen, D. A., & Alexander, G. E. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.03.001 · Cited by 132
Metadata
- Authors
- Farrer, L. A.
- Corresponding author
- Farrer, Lindsay A.
- ORCID
- Farrer, Lindsay A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-10-22
- Volume
- 278
- Issue
- 16
- Pages
- 1349
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W7028228764
- Cited by
- 124
- References
- 0
- Citations by year
- 2026: 16 · 2025: 8 · 2024: 6 · 2023: 12 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, genetic risk, age of onset, sex differences, ethnic differences, African Americans, Hispanic population, Japanese population, genetic heterogeneity, dementia risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
